Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors

Pediatric Blood and Cancer

Volumn 57, Issue 3, 2011, Pages 467-472

  Abosoudah, Ibraheem ^a   Greenberg, Mark L ^b,c   Ness, Kirsten K ^b   Benson, Lee ^d   Nathan, Paul C ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anthracycline; Congestive heart failure; Echocardiogram; Pediatric

Indexed keywords

AMSACRINE; ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; MITOXANTRONE; OXAZAPHOSPHORINE;

ARTICLE; ASYMPTOMATIC DISEASE; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CARDIOMYOPATHY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; ECG ABNORMALITY; ECHOCARDIOGRAPHY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGE OF ONSET; ANTHRACYCLINES; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; NEOPLASMS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS;

EID: 79960171660     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22989     Document Type: Article

References (32)

1. National Cancer Institute. SEER cancer statistics review, 1975-2007 (based on November 2009 seer data submission, posted to the seer web site, 2010). Bethesda, MD: National Cancer Institute; 2010.
2. Gatta G, Zigon G, Capocaccia R, et al. Survival of european children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009;45:992-1005.
3. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: Beginning with the end in mind. J Clin Oncol 2010;28:1276-1281.
4. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
5. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br J Haematol 2005;131:561-578.
6. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol 2002;13:819-829.
7. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-2636.
8. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-815.
9. Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 2001;19:1926-1934.
10. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J Clin Oncol 2001;19:191-196.
11. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
12. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-1677.
13. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-1743.
14. Sorensen K, Levitt G, Sebag-Montefiore D, et al. Cardiac function in Wilms' tumor survivors. J Clin Oncol 1995;13:1546-1556.
15. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009;361:1662-1670.
16. Anderson B. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Pediatr Blood Cancer 2005;44:584-588.
17. van Dalen EC, Michiels EMC, Caron HN, Kremer LCM. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010; Art. No.: CD005006. DOI: 10.1002/14651858.CD005006.pub4.
18. Long term follow up of survivors of childhood cancer: Guideline no. 76. Scottish Collegiate Guidelines Network (SIGN). Available at.
19. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Children's Oncology Group. 2009. Available at.
20. Therapy based long term follow up: Practice statement. United Kingdom Children's Cancer Study Group. 2005. Available at.
21. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group late effects committee and nursing discipline. J Clin Oncol 2004;22:4979-4990.
22. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993;19:197-228.
23. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992;19:529-542.
24. Tolba KA, Deliargyris EN. Cardiotoxicity of cancer therapy. Cancer Invest 1999;17:408-422.
25. Kaski JP, Daubeney PE. Normalization of echocardiographically derived paediatric cardiac dimensions to body surface area: Time for a standardized approach. Eur J Echocardiogr 2009;10:44-45.
26. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary, NC: SAS Institute, Inc.; 2000.
27. Allison PD. Survival analysis using the SAS system, a practical guide. Cary, NC: SAS Institute; 1995. pp. 29-40, 11-184.
28. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the childhood cancer survivor study cohort. Br Med J 2009;339:b4606.
29. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002;20:4517-4522.
30. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820-828.
31. Dai S, Ayres NA, Harrist RB, et al. Validity of echocardiographic measurement in an epidemiological study. Project heartbeat! Hypertension 1999;34:236-241.
32. Geelhoed MJ, Snijders SP, Kleyburg-Linkers VE, et al. Reliability of echocardiographic measurements of left cardiac structures in healthy children. Cardiol Young 2009;19:494-500.